NVO
NYSE Novo Nordisk A/S Sponsored ADR Class B$38.58 ↑ +0.00 (+0.00%) Trading Up from the previous close of $38.58, $0.27 below the day’s high of $38.85
- YTD change
- -24.17%
- vs 20-day SMA
- -2.17%
- vs 200-day SMA
- -15.02%
Price ranges
Price & Performance
+0.60 (+1.58%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 73.1% away from all-time highs of $143.49
- NVO is down 24% since the beginning of the year
- NVO is down 32% over the past 12 months
- NVO is down 10% over the past 1 month
- 1% of all NVO investors are betting against NVO
- Number of investors short NVO has gone down 19% versus last month
NVO reads not so good: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -32.9%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- +3.38%
- vs 8-day SMA
- +1.94%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
